Literature DB >> 11074791

The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.

F Romi1, G O Skeie, J A Aarli, N E Gilhus.   

Abstract

BACKGROUND: Myasthenia gravis (MG) is caused by autoantibodies to the acetylcholine receptor (AChR). Non-AChR muscle autoantibodies are present in many MG serum samples, mainly from patients with thymoma or late-onset MG. The exact relationship between MG severity and several non-AChR muscle antibodies is unknown.
OBJECTIVE: To study the correlation between the severity of MG and the concentration of antibodies against striated muscle tissue sections, titin, citric acid antigen, ryanodine receptor, and AChR.
SETTING: The severity of MG was graded in 146 consecutive patients with MG, and their serum samples were tested for the presence of autoantibodies. Ten patients who were titin antibody positive were observed in longitudinal follow-up.
RESULTS: No significant difference was found in MG severity between late-onset and thymoma MG. Titin, citric acid antigen, and ryanodine receptor antibodies occurred significantly more often among patients with severe MG than among patients with less severe disease. Changes in MG severity correlated with changes in titin antibody titer in the individual patient. Titin antibodies showed a better longitudinal correlation with disease severity than the AChR antibodies.
CONCLUSIONS: Non-AChR muscle autoantibodies occurred more frequently in severe MG regardless of MG subgroup. Thymoma per se does not generate a more severe MG. It may well be the presence of a humoral immune response to non-AChR muscle antigens such as titin, citric acid antigen, and ryanodine receptor that leads to a severe disease, not the presence of thymoma or a late age of onset. These antibodies can serve as important prognostic markers in MG regardless of the presence of thymoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11074791     DOI: 10.1001/archneur.57.11.1596

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  11 in total

1.  Intercommunication between the neuroendocrine and immune systems: focus on myasthenia gravis.

Authors:  Jacqueline Mays; Cherié L Butts
Journal:  Neuroimmunomodulation       Date:  2011-09-22       Impact factor: 2.492

Review 2.  Muscle giants: molecular scaffolds in sarcomerogenesis.

Authors:  Aikaterini Kontrogianni-Konstantopoulos; Maegen A Ackermann; Amber L Bowman; Solomon V Yap; Robert J Bloch
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

3.  Predictors of outcome of myasthenic crisis.

Authors:  Nan Liu; Qi Liu; Xiujuan Wu; Kangding Liu; Quo Vadis
Journal:  Neurol Sci       Date:  2014-07-25       Impact factor: 3.307

4.  The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis.

Authors:  Xiang-Jun Chen; Jian Qiao; Bao-Guo Xiao; Chuan-Zhen Lu
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

Review 5.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

Review 6.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

7.  Myasthenia gravis: a review.

Authors:  Annapurni Jayam Trouth; Alok Dabi; Noha Solieman; Mohankumar Kurukumbi; Janaki Kalyanam
Journal:  Autoimmune Dis       Date:  2012-10-31

8.  Three types of striational antibodies in myasthenia gravis.

Authors:  Shigeaki Suzuki; Kimiaki Utsugisawa; Yuriko Nagane; Norihiro Suzuki
Journal:  Autoimmune Dis       Date:  2011-07-17

9.  Bilateral pseudo-internuclear ophthalmoplegia in a patient with myasthenia gravis.

Authors:  Cynthia K McClard; Lance J Lyons; Sushma Yalamanchili
Journal:  Am J Ophthalmol Case Rep       Date:  2018-09-19

10.  A case of late-onset, thymoma-associated myasthenia gravis with ryanodine receptor and titin antibodies and concomitant granulomatous myositis.

Authors:  M I Stefanou; L Komorowski; S Kade; A Bornemann; U Ziemann; M Synofzik
Journal:  BMC Neurol       Date:  2016-09-13       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.